Modern Strategies for the Therapy of Persistent Bronchial Asthma in Adolescents

Bronchial asthma remains one of the most common non-infectious diseases. In children, the highest prevalence and incidence of asthma is observed in adolescence. Difficulties in achieving and maintaining control over the disease in adolescents are due to the peculiarities of their socio-psychological adaptation, low adherence to therapy, and poor doctor-patient interaction. To achieve maximum control over the disease in children and adolescents suffering from moderate bronchial asthma, according to current guidelines, combined drugs should be used. A number of conciliation documents on asthma adopted the concept of using a single inhaler from the third stage of treatment, which is used both as a basic therapy and for relieving exacerbations. A large number of studies have demonstrated successful experience with the use of such tactics, including in adolescents in real clinical practice. It is proved that this approach increases adherence to therapy, reduces the risk of exacerbations, and improves the control over the disease. However, further research is needed, because therapy with a single inhaler has age limits.

1. eaaci.org [Internet]. Akdis CA, Agache I, et al. Global atlas of allergy. European Academy of Allergy and Clinical Immunology; 2014. 406 p. [cited 2017 May 17]. Available from: http://www. eaaci.org/globalatlas/GlobalAtlasAllergy.pdf.

2. who.int [Internet]. World Health Organization. Asthma [cited 2017 May 17]. Available from: http://www.who.int/mediacentre/ factsheets/fs307/en/.

3. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7(1):12. doi: 10.1186/1939-4551-7-12.

4. Pearce N, Ait-Khaled N, Beasley R, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2007;62(9):758–766. doi: 10.1136/thx.2006.070169.

5. cdc.gov. [Internet]. Centers for Disease Control and Prevention (CDC). Most Recent Asthma Data [cited 2017 May 17]. Available from: http://www.cdc.gov/asthma/most_recent_data.htm.

6. Аллергия у детей: от теории — к практике / Под ред. Л.С. Намазовой-Барановой. — М.: Союз педиатров России; 2011. — 668 с. [Allergiya u detei: ot teorii — k praktike. Ed by L.S. Namazova-Baranova. Moscow: Soyuz pediatrov Rossii; 2011. 668 p. (In Russ).]

7. Статистическая информация Министерства здравоохранения РФ. [Statisticheskaya informatsiya Ministerstva zdravookhraneniya RF. (In Russ).] Доступно по: http://www.rosminzdrav.ru/documents/6686-statisticheskaya-informatsiya Ссылка активна на 04.09.2017.

8. Статистическая информация Министерства здравоохранения РФ. [Statisticheskaya informatsiya Ministerstva zdravookhraneniya RF. (In Russ).] Доступно по: https://www.rosminzdrav.ru/documents/9479-statisticheskaya-informatsiya-za-2014. Ссылка активна 01.09.2017.

9. who.int [Internet]. World Health Organization. Adolescent health [cited 2017 May 17]. Available from: http://www.who.int/topics/ adolescent_health/en/.

10. Pijnenburg MW, Baraldi E, Brand PL, et al. Monitoring asthma in children. Eur Respir J. 2015;45(4):906–925. doi: 10.1183/09031936.00088814.

11. Новик Г.А., Вишнева Е.А., Намазова-Баранова Л.С. Приверженность: роль в достижении контроля над бронхиальной астмой у детей // Педиатрическая фармакология. — 2015. — Т.12. — №2 — С. 190–196. [Novik GA, Vishneva EA, Namazova-Baranova LS. Adherence: its role in achieving control over bronchial asthma in children. Pediatric pharmacology. 2015;12(2):190–196. (In Russ).] doi: 10.15690/pf.v12i2.1282.

12. Вишнева Е.А., Намазова-Баранова Л.С., Алексеева А.А., и др. Новые методы взаимодействия врача и пациента в достижении контроля над болезнью. / Сборник тезисов XVIII Съезда педиатров России с международным участием «Актуальные проблемы педиатрии» (2017 г.). [CD-ROM]. — М.: ПедиатрЪ; 2017. [Vishneva EA, Namazova-Baranova LS, Alekseeva AA, et al. Novye metody vzaimodeistviya vracha i patsienta v dostizhenii kontrolya nad bolezn’yu. (Conference proceedigs) XVIII S»ezd pediatrov Rossii s mezhdunarodnym uchastiem «Aktual’nye prob-

13. Вишнева Е.А., Намазова-Баранова Л.С., Алексеева А.А., и др. Бронхиальная астма у детей. Достижение контроля и предотвращение обострений // Фарматека. — 2014. — №1 — С. 33–39. [Vishneva EA, Namazova-Baranova LS, Alekseeva AA, et al. Bronkhial’naya astma u detei. Dostizhenie kontrolya i predotvrashchenie obostrenii. Farmateka. 2014;(1):33–39. (In Russ).]

14. Foster JM, Smith L, Bosnic-Anticevich SZ, et al. Identifying patient-specific beliefs and behaviours for conversations about adherence in asthma. Intern Med J. 2012;42(6):e136–e144. doi: 10.1111/j.1445-5994.2011.02541.x.

15. Santos Pde M, D’Oliveira A Jr, Noblat Lde A, et al. Predictors of adherence to treatment in patients with severe asthma treated at a referral center in Bahia, Brazil. J Bras Pneumol. 2008;34(12):995–1002.

16. De Simoni A, Horne R, Fleming L, et al. What do adolescents with asthma really think about adherence to inhalers? Insights from a qualitative analysis of a UK online forum. BMJ Open. 2017;7(6):e015245. doi: 10.1136/bmjopen-2016-015245.

17. Morton RW, Everard ML, Elphick HE. Adherence in childhood asthma: the elephant in the room. Arch Dis Child. 2014;99(10):949– 953. doi: 10.1136/archdischild-2014-306243.

18. Klok T, Kaptein AA, Brand PLP. Non-adherence in children with asthma reviewed: The need for improvement of asthma care and medical education. Pediatr Allergy Immunol. 2015;26(3):197–205. doi: 10.1111/pai.12362.

19. ginasthma.org [Internet]. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, revised 2017. [cited 2017 May 17]. Available from: http://ginasthma.org/.

20. Федеральные клинические рекомендации по оказанию медицинской помощи детям с бронхиальной астмой. — М.; 2016. — 33 с. [Federal’nye klinicheskie rekomendatsii po okazaniyu meditsinskoi pomoshchi detyam s bronkhial’noi astmoi. Moscow; 2016. 33 p. (In Russ).]

21. van den Bemt L, Kooijman S, Linssen V, et al. How does asthma influence the daily life of children? Results of focus group interviews. Health Qual Life Outcomes. 2010;8:5. doi: 10.1186/1477-7525-8-5.

22. Государственный реестр лекарственных средств. Безопасность лекарственных препаратов. [Gosudarstvennyi reestr lekarstvennykh sredstv. Bezopasnost’ lekarstvennykh preparatov. (In Russ).] Доступно по: https://grls.rosminzdrav.ru/. Ссылка активна на 01.09.2017.

23. aaia.ca [Internet]. Allergy/Asthma Information Association. A new treatment strategy for asthma — single inhaler maintenance and reliever therapy (SMART) [cited 2017 May 17]. Available from: http://www.aaia.ca/en/new_treatment_strategy_for_asthma.htm.

24. Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;(4):CD007313. doi: 10.1002/14651858.CD007313.pub3.

25. Vogelmeier C, D’Urzo A, Pauwels R, et al. Budesonide/for-moterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J. 2005;26(5):819–828. doi: 10.1183/09031936.05.00028305.

26. Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged 16 years) with asthma: a sub-analysis of the COSMOS study. Clin Drug Investig. 2012;32(7):439–449. doi: 10.2165/11598840-000000000-00000.

27. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013;1(1):32–42. doi: 10.1016/S2213-2600(13)70007-9.

28. de Bilderling G, Smal D, Bradatan E. [Formoterol-budesonide combination for maintenance and relief in children and adolescents with asthma. (In French).] Rev Med Liege. 2016;71(12):546–550.

29. Jenkins CR, Eriksson G, Bateman ED, et al. Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulm Med. 2017;17(1):65. doi: 10.1186/ s12890-017-0401-y.

30. O’Byrne PM, FitzGerald JM, Zhong N, et al. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials. Trials. 2017;18(1):12. doi: 10.1186/s13063-016-1731-4.